Retatrutide is a highly anticipated, investigational peptide being developed for weight management. It stands apart as a “tri-agonist,” activating three different hormone receptors: GLP-1, GIP, and the glucagon receptor. This multi-pronged approach is designed to synergistically control appetite, enhance energy expenditure, and improve insulin sensitivity. Early-phase clinical trials have shown unprecedented levels of weight loss, surpassing even powerful dual-agonists like tirzepatide. While not yet commercially available, Retatrutide represents the next frontier in metabolic pharmacotherapy, with the potential to set a new standard for treating obesity and related conditions.
For research use only. Not for human consumption.
Reviews
There are no reviews yet.